Table 2.
Selected parameters used in HCV transmission model for Georgia
| Prior range* | Posterior median (IQR) | |
|---|---|---|
| Average duration of injecting (years) among PWID aged <29 years | 5–50 | 17·3 (10·9–29·8) |
| Average duration of injecting (years) among PWID aged 30–49 years | 5–50 | 38·1 (30·6–44·3) |
| Average duration of injecting (years) among PWID aged ≥50 years | 5–50 | 29·5 (18·6–38·4) |
| Standardised mortality ratio for PWID26 | 7·2–11·3 | 9·0 (8·1–9·9) |
| Year that increase in PWID recruitment started10, 11 | 1980–95 | 1987 (1984–90) |
| Duration of period of increase in PWID recruitment (years) | 1–30 | 18·4 (13·0–22·4) |
| Year that decrease in general population transmission started13, 14 | 1994–200013, 14 | 1997 (1995–1998) |
| Relative risk of HCV transmission in general population after decrease | 0·01–0·50 | 0·22 (0·12–0·34) |
| Relative risk of HCV transmission on OST28 | 0·40–0·6322 | 0·52 (0·47–0·57) |
| Relative risk of PWID HCV transmission risk due to NSP from 2002† | 0·00–1·00 | 0·26 (0·14–0·42) |
| Relative risk of PWID HCV transmission risk due to NSP from 2012 | 0·00–1·00 | 0·19 (0·10–0·29) |
References indicate where prior ranges were obtained from. PWID=people who inject drugs. HCV=hepatitis C virus. OST=opioid substitution therapy. NSP=needle and syringe programmes.
*
All priors were uniformly distributed.